کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1928549 | 1050371 | 2014 | 5 صفحه PDF | دانلود رایگان |
• We investigated quinolinone derivatives as novel FLT3 inhibitors.
• These novel FLT3 inhibitors inhibit FLT3 and FLT3 induced STAT5 phosphorylation.
• FLT3 inhibitors induce growth inhibition and apoptotic cell death in AML cells.
• Quinolinone derivatives are potential lead structures for anti-leukemic agents.
Recently some fms-like tyrosine kinase 3 (FLT3) inhibitors have shown good efficacy in acute myeloid leukemia (AML) patients. In an effort to develop anti-leukemic drugs, we investigated quinolinone derivatives as novel FLT3 inhibitors. Two substituted quinolinones, KR65367 and KR65370 were subjected to FLT3 kinase activity assay and showed potent inhibition against FLT3 kinase activity in vitro, with IC50 of 2.7 and 0.57 nM, respectively. As a measure of selectivity, effects on the activity of other kinases were also tested. Both compounds have negligible activity against Met, Ron, epidermal growth factor receptor, Aurora A, Janus kinase 2, and insulin receptor; with IC50 greater than 10 μM. KR compounds showed strong growth inhibition in MV4;11 AML cells and increased the apoptotic cell death in flow cytometric analyses. A decrease in STAT5 phosphorylation by KR compounds was observed in MV4;11 cells. Furthermore, in vitro evaluation of compounds structurally related to KR65367 and KR65370 showed a good structure-activity relationship.
Journal: Biochemical and Biophysical Research Communications - Volume 445, Issue 3, 14 March 2014, Pages 561–565